All Things Cardio-Oncology

Joshua Levenson MD is an Assistant Professor of Medicine at the University of Pittsburgh School of Medicine. He studied Chemistry at Amherst College followed by medicine at the University of Pittsburgh and internal medicine residency at The University of Michigan. He returned to the University of Pittsburgh Medical Center for Cardiology Fellowship prior to joining faculty in 2017. Dr Levenson is a noninvasive cardiologist, cardiac imager, and clinician educator. He serves as Director of UPMC’s Center for Cardio-Oncology, co-Director of Noninvasive at UPMC Shadyside, and Associate Director of UPMC’s Cardiology Fellowship.

Dr. Isabella Mahe is the first author of the API-CAT trial and in this episode she reviews predictors associated with clinically relevant bleeding. Join us for for an in-depth discussion on predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism: a post-hoc analysis of a randomised, non-inferiority trial (API-CAT).

Dr. Suvro Banerjee is a distinguished Cardiologist based in Kolkata, West Bengal, with an impressive experience of 26 years in the field of cardiology. Holding multiple prestigious qualifications including MBBS, MD, MRCP, FRCP, FICC, FCSI, FESC, FACC, and FSCAI. As a testament to his leadership and dedication to the field, he has held several notable positions, including Secretary of the Cardiological Society of India, West Bengal Branch, from 2017 to 2019, and has actively participated in multiple organizations such as the West Bengal Academy of Echocardiography and the Royal College of Physicians in Edinburgh. He has been active in cardio-oncology care in Kolkata for the past few years. In this episode he describes the developing interest in cardio-oncology care throughout India.

Join Dr Emily Tomasulo (Pennsylvania Hospital, US) and Dr Robert S. Copeland Halperin (Northwell Health System, US) for an in-depth discussion on BTK Inhibitor-Associated Hypertension.

With the rapid increase in the use of BTK inhibitors managing CV risk is increasingly challenging and important. In this episode leading experts from the University of Pennsylvania medical school guide us through some of these complexities. Watch to the full webinar here: https://www.radcliffecardiology.com/webinars/managing-cv-risk-patients-cll

Dr. Emily Tomasulo is a Hematologist/Oncologist who specializes in B-cell lymphoma and cellular therapy at Pennsylvania Hospital and the Hospital of the University of Pennsylvania. She sits on ECOG-ACRIN Leukemia Committee and her research and clinical interests focus on the use of targeted and cellular therapies in B-cell malignancies with particular attention to cardiovascular adverse effects.

Dr. Michael Fradley is an Associate Professor of Clinical Medicine in the Division of Cardiology at the Perelman School of Medicine at the University of Pennsylvania and Medical Director of the Thalheimer Center for Cardio-Oncology. He trained at Yale University, Johns Hopkins University, and Massachusetts General Hospital. His clinical and research interests focus on arrhythmic complications of cancer therapies. He currently serves as President of the International Cardio-Oncology Society (IC-OS).